Correlation between N-terminal pro-atrial natriuretic peptide, corin, and target organ damage in hypertensive disorders of pregnancy

  1. The objective was to evaluate the correlation between N-terminal pro-atrial natriuretic peptide (NT-proANP), corin and the severity of target organ injury in hypertensive disorders of pregnancy.
  2. A total of 78 women with hypertensive disorders of pregnancy and 49 normotensive pregnancies were enrolled. Bio Med Frontiers The clinical characteristics, laboratory index and echocardiogram results were collected.
  3. NT-proANP, corin, sFlt-1 and PlGF levels were measured. A receiver’s operating characteristics (ROC) curve was performed to evaluate the efficacy of predicting target organ injury in the HDP group. The NT-proANP, corin, and sFlt-1/PlGF ratio were increased in the HDP group (p < .05).
  4. The area under the curve (AUC) predicted by NT-proANP and corin were larger than sFlt-1/PlGF ratio (0.779, 0.867, and 0.766, respectively).
  5. The creatinine and urine protein were significantly increased, while the estimated glomerular filtration rate (eGFR) was dramatically decreased in the HDP group (p < .05 each).
  6. The left atrial diameter (LAD), left atrial volume index (LAVI), left ventricular posterior wall thickness (LVPWT), and left ventricular septal thickness (LVST) were larger in the HDP group (p < .001 each).
  7. The NT-proANP/corin levels were positively correlated with LAD, creatinine, and urine protein, and negatively correlated with eGFR in HDP group (p < .05 each).
  8. Multiple regressions demonstrated that NT-proANP was an independent risk factor of LAD and urine protein, and corin was an independent risk factor of creatinine and eGFR in HDP group. NT-proANP and corin may be reliable biomarkers for evaluating the severity of target organ damage in the hypertensive disorders of pregnant patients.

Wasp venom peptide improves the proapoptotic activity of alendronate sodium in A549 lung cancer cells.

 Lung cancer in men and women is considered the leading cause for cancer-related mortality worldwide. Anti-cancer peptides represent a potential untapped reservoir of effective cancer therapy.
Box-Behnken response surface design was applied for formulating Alendronate sodium (ALS)-mastoparan peptide (MP) nanoconjugates using Design-Expert software.
The optimization process aimed at Our Supplier minimizing the size of the prepared ALS-MP nanoconjugates. ALS-MP nanoconjugates’ particle size, encapsulation efficiency and release profile were determined. Cytotoxicity, cell cycle, annexin V staining and caspase 3 analyses on A549 cells were carried out for the optimized formula.
The results revealed that the optimized formula was of 134.91±5.1 nm particle size. The novel ALS-MP demonstrated the lowest IC50 (1.3 ± 0.34 μM) in comparison to ALS-Raw (37.6 ± 1.79 μM).
Thus, the results indicated that when optimized ALS-MP nanoconjugate was used, the IC50 of ALS was also reduced by half. Cell cycle analysis demonstrated a significantly higher percentage of cells in the G2-M phase following the treatment with optimized ALS-MP nanoconjugates.

Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors.

Data about the optimal timing for the initiation of peptide receptor radionuclide therapy (PRRT) for advanced, well-differentiated enteropancreatic neuroendocrine tumors are lacking.
To evaluate the association of upfront PRRT vs upfront chemotherapy or targeted therapy with progression-free survival (PFS) among patients with advanced enteropancreatic neuroendocrine tumors who experienced disease progression after treatment with somatostatin analogues (SSAs).
This retrospective, multicenter cohort study analyzed the clinical records from 25 Italian oncology centers for patients aged 18 years or older who had unresectable, locally advanced or metastatic, well-differentiated, grades 1 to 3 enteropancreatic neuroendocrine tumors and received either PRRT or chemotherapy or targeted therapy after experiencing disease progression after treatment with SSAs between January 24, 2000, and July 1, 2020.
Propensity score matching was done to minimize the selection bias.
Upfront PRRT or upfront chemotherapy or targeted therapy.
 The main outcome was the difference in PFS among patients who received upfront PRRT vs among those who received upfront chemotherapy or targeted therapy.
A secondary outcome was the difference in overall survival between these groups. Hazard ratios (HRs) were fitted in a multivariable Cox proportional hazards regression model to adjust for relevant factors associated with PFS and were corrected for interaction with these factors.
  • Of 508 evaluated patients (mean ([SD] age, 55.7 [0.5] years; 278 [54.7%] were male), 329 (64.8%) received upfront PRRT and 179 (35.2%) received upfront chemotherapy or targeted therapy. The matched group included 222 patients (124 [55.9%] male; mean [SD] age, 56.1 [0.8] years), with 111 in each treatment group.
  • Median PFS was longer in the PRRT group than in the chemotherapy or targeted therapy group in the unmatched (2.5 years [95% CI, 2.3-3.0 years] vs 0.7 years [95% CI, 0.5-1.0 years]; HR, 0.35 [95% CI, 0.28-0.44; P < .001]) and matched (2.2 years [95% CI, 1.8-2.8 years] vs 0.6 years [95% CI, 0.4-1.0 years]; HR, 0.37 [95% CI, 0.27-0.51; P < .001]) populations.
  • No significant differences were shown in median overall survival between the PRRT and chemotherapy or targeted therapy groups in the unmatched (12.0 years [95% CI, 10.7-14.1 years] vs 11.6 years [95% CI, 9.1-13.4 years]; HR, 0.81 [95% CI, 0.62-1.06; P = .11]) and matched (12.2 years [95% CI, 9.1-14.2 years] vs 11.5 years [95% CI, 9.2-17.9 years]; HR, 0.83 [95% CI, 0.56-1.24; P = .36]) populations.
  • The use of upfront PRRT was independently associated with improved PFS (HR, 0.37; 95% CI, 0.26-0.51; P < .001) in multivariable analysis.
  • After adjustment of values for interaction, upfront PRRT was associated with longer PFS regardless of tumor functional status (functioning: adjusted HR [aHR], 0.39 [95% CI, 0.27-0.57]; nonfunctioning: aHR, 0.29 [95% CI, 0.16-0.56]), grade of 1 to 2 (grade 1: aHR, 0.21 [95% CI, 0.12-0.34]; grade 2: aHR, 0.52 [95% CI, 0.29-0.73]), and site of tumor origin (pancreatic: aHR, 0.41 [95% CI, 0.24-0.61]; intestinal: aHR, 0.19 [95% CI, 0.11-0.43]) (P < .001 for all). Conversely, the advantage was not retained in grade 3 tumors (aHR, 0.31; 95% CI, 0.12-1.37; P = .13) or in tumors with a Ki-67 proliferation index greater than 10% (aHR, 0.73; 95% CI, 0.29-1.43; P = .31).
 In this cohort study, treatment with upfront PRRT in patients with enteropancreatic neuroendocrine tumors who had experienced disease progression with SSA treatment was associated with significantly improved survival outcomes compared with upfront chemotherapy or targeted therapy.
Further research is needed to investigate the correct strategy, timing, and optimal specific sequence of these therapeutic options.

Research progress in the screening and evaluation of umami peptides.

  • Umami is an important element affecting food taste, and the development of umami peptides is a topic of interest in food-flavoring research.
  • The existing technology used for traditional screening of umami peptides is time-consuming and labor-intensive, making it difficult to meet the requirements of high-throughput screening, which limits the rapid development of umami peptides.
  • The difficulty in performing a standard measurement of umami intensity is another problem that restricts the development of umami peptides.
  • The existing methods are not sensitive and specific, making it difficult to achieve a standard evaluation of umami taste.
  • This review summarizes the umami receptors and umami peptides, focusing on the problems restricting the development of umami peptides, high-throughput screening, and establishment of evaluation standards.
  • The rapid screening of umami peptides was realized based on molecular docking technology and a machine learning method, and the standard evaluation of umami could be realized with a bionic taste sensor.
  • The progress of rapid screening and evaluation methods significantly promotes the study of umami peptides and increases its application in the seasoning industry.

Peptide Backbone Directed Self-Assembly of Merocyanine Oligomers into Duplex Structures.

The pseudopeptide backbone provided by N-(2-aminoethyl)-glycine oligomers with attached nucleobases has been widely utilized in peptide nucleic acids (PNAs) as DNA mimics.
Here we demonstrate the suitability of this backbone for the formation of structurally defined dye stacks.
Toward this goal a series of peptide merocyanine (PMC) dye oligomers connected to N-(2-aminoethyl)-glycine backbone were prepared through peptide synthesis.

Mast Cell-Degranulating Peptide (MCD Peptide) / Peptide 401

004-04 PHOENIX PEPTIDE 100 μg 140.4 EUR

Peptide T

057-01 PHOENIX PEPTIDE 5 mg 140.4 EUR

FGL Peptide

073-36 PHOENIX PEPTIDE 100 μg 214.92 EUR

APK peptide

076-81 PHOENIX PEPTIDE 200 μg 199.8 EUR

NEF peptide

076-83 PHOENIX PEPTIDE 500 μg 140.4 EUR

SHA peptide

076-84 PHOENIX PEPTIDE 500 μg 177.12 EUR

YSY peptide

076-86 PHOENIX PEPTIDE 100 μg 230.04 EUR

PSTAIR Peptide

070-61 PHOENIX PEPTIDE 500 μg 129.6 EUR

PGMtide Peptide

040-69 PHOENIX PEPTIDE 100 μg 316.44 EUR

Peptide E / 3200-Dalton Adrenal Enkephalin-Containing Peptide (Bovine)

024-57 PHOENIX PEPTIDE 200 μg 86.4 EUR

Adjuvant Peptide

070-05 PHOENIX PEPTIDE 500 μg 36.72 EUR

proSex peptide (20-55)

040-30 PHOENIX PEPTIDE 100 μg 355.32 EUR

proSex peptide (28-55)

040-31 PHOENIX PEPTIDE 100 μg 282.96 EUR

proSex peptide (40-55)

040-32 PHOENIX PEPTIDE 100 μg 214.92 EUR

Peptide-epsilon

058-22 PHOENIX PEPTIDE 500 μg 114.48 EUR

Delicious Peptide

070-21 PHOENIX PEPTIDE 5 mg 160.92 EUR

Peptide F-9

038-06 PHOENIX PEPTIDE 200 μg 58.32 EUR

Sturgeon Peptide (137-158)

021-94 PHOENIX PEPTIDE 100 μg 177.12 EUR
Our concentration-, temperature- and solvent-dependent UV/Vis absorption studies show that under the control of dipole-dipole interactions, smaller-sized oligomers consisting of one, two or three dyes self-assemble into defined duplex structures containing two up to six chromophores.
In contrast, upon further extension of the oligomer, the chosen peptide backbone cannot direct the formation of a defined duplex architecture anymore due to intramolecular aggregation between the dyes. For all aggregate species a moderate aggregation-induced emission enhancement is observed.

Leave a Comment

Your email address will not be published.

Scroll to Top